184 related articles for article (PubMed ID: 33587988)
1. Polyglutamic acid-based crosslinked doxorubicin nanogels as an anti-metastatic treatment for triple negative breast cancer.
Duro-Castano A; Sousa-Herves A; Armiñán A; Charbonnier D; Arroyo-Crespo JJ; Wedepohl S; Calderón M; Vicent MJ
J Control Release; 2021 Apr; 332():10-20. PubMed ID: 33587988
[TBL] [Abstract][Full Text] [Related]
2. Bio-derived poly(gamma-glutamic acid) nanogels as controlled anticancer drug delivery carriers.
Bae HH; Cho MY; Hong JH; Poo H; Sung MH; Lim YT
J Microbiol Biotechnol; 2012 Dec; 22(12):1782-9. PubMed ID: 23221543
[TBL] [Abstract][Full Text] [Related]
3. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment.
Arroyo-Crespo JJ; Armiñán A; Charbonnier D; Balzano-Nogueira L; Huertas-López F; Martí C; Tarazona S; Forteza J; Conesa A; Vicent MJ
Biomaterials; 2018 Dec; 186():8-21. PubMed ID: 30278346
[TBL] [Abstract][Full Text] [Related]
5. Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.
Cheng B; Gao F; Maissy E; Xu P
Acta Biomater; 2019 Jan; 84():378-390. PubMed ID: 30528604
[TBL] [Abstract][Full Text] [Related]
6. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
[TBL] [Abstract][Full Text] [Related]
7. Folic acid based carbon dot functionalized stearic acid-g-polyethyleneimine amphiphilic nanomicelle: Targeted drug delivery and imaging for triple negative breast cancer.
Sarkar P; Ghosh S; Sarkar K
Colloids Surf B Biointerfaces; 2021 Jan; 197():111382. PubMed ID: 33160259
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment.
Khondee S; Chittasupho C; Tima S; Anuchapreeda S
Curr Drug Deliv; 2018; 15(3):406-416. PubMed ID: 28707580
[TBL] [Abstract][Full Text] [Related]
9. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
[TBL] [Abstract][Full Text] [Related]
10. A dual receptors-targeting and size-switchable "cluster bomb" co-loading chemotherapeutic and transient receptor potential ankyrin 1 (TRPA-1) inhibitor for treatment of triple negative breast cancer.
Wang Y; Yin S; Mei L; Yang Y; Xu S; He X; Wang M; Li M; Zhang Z; He Q
J Control Release; 2020 May; 321():71-83. PubMed ID: 32035191
[TBL] [Abstract][Full Text] [Related]
11. Biotin receptor-targeting nanogels loaded with methotrexate for enhanced antitumor efficacy in triple-negative breast cancer in vitro and in vivo models.
Sadat Abolmaali S; Zarenejad S; Mohebi Y; Najafi H; Javanmardi S; Abedi M; Mohammad Tamaddon A
Int J Pharm; 2022 Aug; 624():122049. PubMed ID: 35878871
[TBL] [Abstract][Full Text] [Related]
12. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeted and nitric oxide-generated nanogels of keratin and hyaluronan for enhanced cancer therapy.
Sun Z; Yi Z; Cui X; Chen X; Su W; Ren X; Li X
Nanoscale; 2018 Jul; 10(25):12109-12122. PubMed ID: 29915821
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
15. Ferroptosis-enhanced chemotherapy for triple-negative breast cancer with magnetic composite nanoparticles.
Zhang J; Zhou K; Lin J; Yao X; Ju D; Zeng X; Pang Z; Yang W
Biomaterials; 2023 Dec; 303():122395. PubMed ID: 37988899
[TBL] [Abstract][Full Text] [Related]
16. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
17. Naturally derived DNA nanogels as pH- and glutathione-triggered anticancer drug carriers.
Chen YF; Hsu MW; Su YC; Chang HM; Chang CH; Jan JS
Mater Sci Eng C Mater Biol Appl; 2020 Sep; 114():111025. PubMed ID: 32994007
[TBL] [Abstract][Full Text] [Related]
18. Dual-Loaded Liposomes Tagged with Hyaluronic Acid Have Synergistic Effects in Triple-Negative Breast Cancer.
Dong S; Bi Y; Sun X; Zhao Y; Sun R; Hao F; Sun Y; Wang Y; Li X; Deng W; Liu X; Ha J; Teng L; Gong P; Xie J; Kim BYS; Yang Z; Jiang W; Teng L
Small; 2022 Apr; 18(16):e2107690. PubMed ID: 35277914
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
20. Depletion of Mannose Receptor-Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast Cancer Progression in Mice.
Lepland A; Malfanti A; Haljasorg U; Asciutto EK; Pickholz M; Bringas M; Đorđević S; Salumäe L; Peterson P; Teesalu T; Vicent MJ; Scodeller P
Cancer Res Commun; 2022 Jun; 2(6):533-551. PubMed ID: 36923553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
